# Insights into tumor vaccines for elderly individuals in the context of immunosenescence

## TL;DR

This paper reviews how aging affects cancer vaccine effectiveness in elderly individuals and suggests strategies to improve it.

## Contribution

The paper proposes novel strategies to enhance cancer vaccine efficacy in elderly individuals by addressing immunosenescence.

## Key findings

- Immunosenescence impairs vaccine-induced immunity in elderly individuals.
- Six strategies are proposed to improve cancer vaccine efficacy in the elderly.
- Tailoring vaccines to elderly-specific immunosenescence could reduce cancer burden.

## Abstract

The global burden of cancer is increasing tremendously, particularly among individuals aged 60 years and older, and has emerged as a critical public health concern. Cancer vaccine-induced immunity can recognize and eliminate tumor cells with high specificity and low toxicity. Nevertheless, immunosenescence increases the risk and severity of cancers in elderly individuals while impairing vaccine-induced immunity. Furthermore, much oncology research has predominantly focused on adults, often neglecting the potential contributions of aging individuals to tumor progression. Elucidating the interactions between the immunosenescent microenvironment and tumorigenesis can inspire the development of more effective cancer vaccines tailored to the characteristics of elderly individuals, thereby alleviating the global cancer burden. In this review, we analyze how the immunosenescent microenvironment impacts tumor development and summarize existing strategies aimed at enhancing cancer vaccine efficacy, drawing inspiration from insights into immunosenescence. We believe that this review will inspire efforts toward creating individualized cancer vaccines for the elderly.

Emerging strategies aimed at enhancing the efficacy of cancer vaccines in elderly individuals include inhibiting inflammatory signals, promoting antigen presentation, mitigating T-cell immunosenescence, eliminating senescent cells, utilizing immunomodulatory adjuvants, and employing senescent tumor cell-derived vaccines. (Created with Adobe illustrator)

Diagram illustrating six strategies to combat tumor progression: 1. Inhibiting inflammatory signals like IL-33, IL-1α, and IL-1β. 2. Enhancing antigen presentation via cross-presentation and reversing immunosuppression. 3. Mitigating T-cell immunosenescence through photochemotherapy and telomere interaction. 4. Eliminating senescent cells using vaccines and CAR-T cells. 5. Utilizing immunomodulatory adjuvants to boost antigen presentation and reduce inflammation. 6. Employing vaccines from senescent tumor cell derivatives to activate immune response and target lymph nodes. Central diagram shows aging in the tumor microenvironment.